Fosun Pharma to acquire controlling stake in Green Valley

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) is set to acquire a controlling 53% equity stake in Green Valley (Shanghai) Pharmaceuticals Technology Co., Ltd. through its subsidiary, Fosun Pharmaceutical Industrial. This investment, totaling RMB 141,248.1633, will be executed through a combination of equity transfer (RMB 14,300) and subscription to new registered capital (RMB 126,948.1633). The transaction also includes a phased transfer of 866.7347 million Yuan of registered capital to an SPV jointly established by Fosun Pharma Industrial and Green Valley's founders.

The valuation report, prepared by Shanghai Dongzhou Asset Appraisal Co., Ltd., assessed Green Valley's total equity value at RMB 1,674,000,000.00 as of September 30, 2025. Green Valley, a key innovator in Alzheimer's treatments, has a core product, GV-971 (sodium oligomannate capsules), whose conditional registration expired in November 2024, necessitating further clinical trials for re-commercialization.

The acquisition is aimed at enriching Fosun Pharma's product pipeline in central nervous system disorders and enhancing its market presence. The company plans to fund the acquisition through self-raised capital. The transaction has been approved by Fosun Pharma's board of directors and is subject to several closing conditions, including the successful completion of clinical trials for GV-971 and its re-entry into the national medical insurance catalog.